

WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)

WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)
Customers also bought
Fibristone 25 Tablet is a selective progesterone receptor modulator containing of Mifepristone. While higher doses are used for different clinical purposes, this strength is primarily indicated for the medical management of uterine fibroids (non-cancerous growths in the uterus). By blocking the effects of the hormone progesterone, which is essential for fibroid growth, it helps significantly reduce fibroid size and control associated symptoms such as heavy menstrual bleeding and pelvic pain. This lower-dose formulation is designed to provide therapeutic benefits while minimising systemic side effects, often serving as a pre-surgical treatment or a long-term management strategy for symptomatic fibroids
Fibristone 25 Tablet belongs to the class of medications known as anti-progestogens. The dose is a low-strength, chronic-use formulation specifically developed for gynaecological health.
Composition and Mechanism: Each tablet contains of Mifepristone. It acts as a competitive antagonist at the progesterone receptor. In the presence of progesterone, Mifepristone binds to the receptors in the uterine tissue (myometrium) and the fibroids themselves, preventing the hormone from "docking" and sending growth signals. This results in fibroid shrinkage and reduced blood supply to the uterine lining, which effectively stops or reduces heavy menstrual flow (menorrhagia).
Major Therapeutic Uses: Fibristone 25 Tablet is primarily indicated for the symptomatic relief of Uterine Leiomyoma (Fibroids). It is used to reduce tumour size before a planned myomectomy or hysterectomy, making the surgery safer and less invasive. It is also used as a medical alternative for women who wish to avoid surgery, providing relief from pelvic pressure and anaemia caused by blood loss. Additionally, in some clinical settings, this low-dose format may be explored for the management of Endometriosis or certain types of progesterone-sensitive meningiomas, under strict specialist guidance.
Benefits and Precautions: The primary benefit of Fibristone 25 Tablet is its ability to provide a "non-surgical" reduction in fibroid distress, allowing many women to regain a normal quality of life without invasive procedures. However, significant precautions are necessary regarding the uterine lining (endometrium). Because it blocks progesterone, the uterine lining may thicken over time (cystic glandular hyperplasia); therefore, regular ultrasound monitoring is required. Precautions are also vital for patients with chronic adrenal failure or severe asthma, as Mifepristone also has anti-glucocorticoid activity. It should be used with caution in women with a history of liver or kidney impairment.
Medical Supervision and Risks: Use of Fibristone 25 Tablet must be strictly supervised by a gynaecologist. Major risks include changes in the endometrial lining and a slight risk of elevated liver enzymes. It is absolutely contraindicated in pregnancy, as it can cause foetal harm or pregnancy loss. It is also contraindicated in patients with undiagnosed vaginal bleeding or suspected uterine malignancy. Patients should be monitored with periodic pelvic ultrasounds and blood tests to ensure the medication is being processed safely. This medication is typically prescribed for a specific duration, such as 3 to 6 months.
Fibristone 25 Tablet (Mifepristone 25mg) is indicated for:
Reducing the size and volume of leiomyomas.
Controlling heavy and prolonged menstrual bleeding.
Shrinking fibroids to facilitate easier surgery.
Relieving the pressure and pain caused by enlarged uterine tissue.
Off-label use for controlling endometrial tissue growth.
Fibristone 25 Tablet offers a "hormone-balancing" approach to uterine health. Its primary medicinal benefit is the interruption of the progesterone-driven growth cycle. For women suffering from fibroids, the uterus can become enlarged, leading to a constant feeling of heaviness and severe anaemia from monthly blood loss. The dose acts as a "silent blocker," occupying the receptors that would otherwise cause the fibroids to expand. This results in a noticeable reduction in uterine bulk, often within the first two months of treatment.
One of the significant advantages of this formulation is its ability to induce "amenorrhoea" (temporary stoppage of periods). For a patient struggling with low iron levels due to heavy bleeding, stopping the cycle allows the body to rebuild its red blood cell count naturally. This significantly improves energy levels and overall well-being. Unlike some other hormone treatments, Mifepristone at this dose does not typically cause the "medical menopause" symptoms (like hot flushes or bone loss) often seen with GnRH agonists.
Furthermore, Fibristone 25 Tablet is designed to offer a bridge to recovery. Whether it is used to make a future surgery more successful or to manage symptoms until menopause (when fibroids naturally shrink), it provides a controlled, pharmacological way to manage a complex condition. For many, this tablet represents a chance to avoid major abdominal surgery while effectively managing the physical and emotional burden of uterine fibroids.
STRICTLY FORBIDDEN. Causes congenital disabilities or loss. Use non-hormonal birth control.
Requires periodic liver function tests (LFTs) if used for long periods.
Use with care; ensure your doctor is aware of any history of kidney disease.
Does not usually affect driving unless you experience significant dizziness.
Regular ultrasound monitoring of the uterus is essential during treatment.
Store Fibristone 25 Tablet at room temperature (below 30°C). Keep the tablets in their original moisture-proof pack. Protect from direct heat, sunlight, and moisture. Keep out of reach of children.
It can significantly increase Mifepristone levels in the body.
Mifepristone blocks the effects of steroids (like Prednisolone).
May increase the risk of side effects by slowing down drug clearance.
May reduce the medication's effectiveness in shrinking fibroids.
The dosage of Fibristone 25 Tablet for uterine fibroids is standardised. For adults, the standard dose is one 25mg tablet once daily.
Treatment usually begins during the first few days of the menstrual period. The duration is typically 3 months, though it can be extended to 6 months based on the patient's response and ultrasound findings. A "break" or drug-free interval is often recommended between courses to allow the uterine lining to shed. Always follow the specific clinical protocol provided by your gynaecological specialist.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed one. Do not take a double 25mg dose, as this increases the risk of hormonal side effects and does not improve the treatment outcome.
Therapeutic Class
Anti-progestogen
Action Class
Progesterone Receptor Antagonist
Chemical Class
Norsteroid derivative
Habit Forming
No
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
More Medicines By Manufacturer
More Medicines With Salt
Top Selling Medicines
Top Selling Devices
Flat ₹100 off on first app order | Use Code: APP100 |
Flat ₹100 off on first app order
USE CODE: APP100
Download Now